Sio Gene Therapies Inc.
SIOX · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1,883 | $336 | $5,542 | $12,606 |
| G&A Expenses | $2,600 | $2,941 | $2,992 | $470 |
| SG&A Expenses | $2,600 | $2,941 | $2,992 | $470 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $47 |
| Operating Expenses | $4,483 | $3,277 | $8,534 | $13,076 |
| Operating Income | -$4,620 | -$3,143 | -$8,534 | -$13,279 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $601 | $63 | $124 | $242 |
| Pre-Tax Income | -$4,019 | -$3,080 | -$8,410 | -$13,037 |
| Tax Expense | -$601 | -$63 | -$4 | $287 |
| Net Income | -$3,418 | -$3,017 | -$8,406 | -$13,324 |
| % Margin | – | – | – | – |
| EPS | -0.046 | -0.041 | -0.11 | -0.18 |
| % Growth | -13.2% | 62.9% | 38.9% | – |
| EPS Diluted | -0.046 | -0.041 | -0.11 | -0.18 |
| Weighted Avg Shares Out | 73,975 | 73,975 | 73,765 | 73,706 |
| Weighted Avg Shares Out Dil | 73,975 | 73,975 | 73,765 | 73,715 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $8 |
| Depreciation & Amortization | $137 | -$134 | $271 | $250 |
| EBITDA | $0 | $0 | $0 | -$12,779 |
| % Margin | – | – | – | – |